Latest Regulatory Clearance News

Eastern Metals Limited has progressed its strategic acquisition of Raptor Resources while completing an initial capital raise and divesting a royalty interest, positioning itself for growth in copper exploration.

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

4DMedical reports a 56% revenue surge in FY25 alongside a strategic $10 million investment from Pro Medicus, advancing its CT, VQ™ lung imaging technology towards FDA clearance.

Astron Corporation has cleared major regulatory hurdles for its Donald Rare Earth and Mineral Sands Project, releasing a robust updated economic study that underscores the project's long-term value and advancing financing discussions.

PainChek Limited has secured a A$7.5 million placement to fuel its international expansion, with US FDA clearance for its adult pain assessment app expected imminently. The company reports strong license growth and a 26% revenue increase year-on-year.

Vonex Limited has taken a key step in its acquisition by Maxo Telecommunications, lodging a draft Scheme Booklet with ASIC that includes an independent expert’s report. This move brings the proposed takeover closer to shareholder approval and regulatory clearance.

Genesis Resources has completed its acquisition of full ownership of the Plavica project in North Macedonia and is advancing environmental studies while preparing for drilling campaigns in Australia’s Northern Territory.

New World Resources has upgraded its Antler Copper Deposit resource to 14.2 million tonnes at 3.8% copper equivalent, secured key permitting milestones, and recommended shareholders accept a $0.067 per share takeover offer from Kinterra Capital.

EMVision Medical Devices has secured ethics approvals for two pivotal clinical studies and received a $400,000 milestone payment, marking significant progress toward commercialising its portable First Responder brain scanner.

Buxton Resources reports significant progress across its exploration portfolio, including earthworks at Centurion, heritage survey completion at Madman, and a major graphite testwork success, while regaining full control of Fraser Range after IGO's exit.

Elanor Investors Group announces a $125 million strategic investment from Rockworth Capital Partners to stabilise its balance sheet and fund growth, including the acquisition of Singapore’s Firmus Capital.

Neurizon Therapeutics has formally responded to the FDA's clinical hold on its lead ALS drug NUZ-001, submitting new animal safety data. The company aims to join the HEALEY ALS Platform Trial by late 2025, pending regulatory approval.